eden | Precision Science. Human Impact.



A patient's chance at diagnosis or treatment should never depend on geography or a fragile supply chain.

We exist to make that true.

October 2026

More than half of us will face cancer or heart disease.

Both early detection and precision treatment depend on the same constrained infrastructure.

That's not just a healthcare challenge—

it's an infrastructure opportunity.

Isotope Shortages Threaten Patient Care and Medical Innovation

> The rare radioisotope is on the cutting-edge of cancer therapy — and in such demand that a shortage recently stalled a promising clinical trial.

— The Journal, *Science*, 2025

- The DOE managed/funded the Medical Isotope Program in the 1990s. Under this program, Sandia National Laboratories nuclear facilities were to become a backup supplier and produce <50% of U.S. demand for Mo-99 at the time.
- Despite Sandia's significant progress towards this goal (estimated at 80% complete) DOE ended the program in 1998 under a **false forecast** that Canada was poised to deliver using their Maple X reactors.
- But scaled Canadian production did not materialize and by 2008 the Maple X program was canceled. Shortages of isotopes led to **delays/cancellations in diagnostic tests** for patients.
- In 2012, Congress passed the American Medical Isotopes Production Act to establish a domestic supply of Mo-99 using LEU. **Several companies have proposed different methods for Mo-99 production, yet none have succeeded to date**.
- Supply chain uncertainty of Mo-99 continues and there is limited global Lu-177 and Cu-64 production capacity.

Nuclear medicine is irreplaceable

Medical isotopes are the molecular tools doctors use to find disease early — and now, increasingly, to treat it precisely.

Molybdenum-99 (Mo-99) – SPECT Imaging

80% of 40M global **diagnostic** imaging procedures

Detects cancer, heart, and metabolic diseases

1%/hr shrinkage from radioactive decay

Copper-64 (Cu-64) - PET Imaging

Next-generation **theranostic** pair with Cu-67

Single molecule to both detect and destroy tumors

5.6%/hr shrinkage from radioactive decay

Lutetium-177 (Lu-177) – Leading Therapeutic

First approved **radiotherapeutics** (2) for prostate cancer

0.4%/hr shrinkage from radioactive decay

Other Activation Isotopes & Fission Products

>90 radiotherapeutics and **theranostics** in clinical trials.

Activation: Tb-161; Fission: Y-90, I-131, Xe-133

Eden supply chain integration

From Isotope Production to Patient Care

Core Capability

Isotope Production

Eden Reactor

Products: Mo-99, Lu-177, Y-90, I-131, Xe-133, Tb-161, Cu-64, Cu-67

Core Capability

Radiochemical Processing & Purification

Eden Integrated Hot Cell Facility Target processing, isotope purification and QA/QC Integrated within Eden operations

Customers / Offtake Partners

CLARITY
CURIUM
itm
Lilly
SHINE
NOVARTIS
Telix

Distribution & Logistics

Handled by downstream partners: Curium, Cardinal Health, GE HealthCare, Siemens Eden supports shipment coordination

Clinical & End-User Applications

Hospitals, Oncology Clinics Patients receive therapies derived from Eden isotopes

Eden is North America's first purpose-built medical isotope reactor

Purpose-built

Designed solely to produce medical isotopes — not adapted from a research or power reactor.

Multiple isotopes, one facility

Mo-99 for diagnostics. Lu-177 for cancer therapy. Cu-64 for next-gen imaging. All from one reactor.

U.S. soil

Eunice, New Mexico. Eliminates supply risk from foreign reactors and aging infrastructure.

Lowest cost

Integrated production and processing on one site means highest yield and the lowest cost per dose.

Eden New Mexico Facility Site Location




October 2026

Eden medical isotope facility (EMIF)


World's first integrated reactor and hot cell facility

365 days/yr dual-purpose fission produces isotopes concurrently and continuously: US demand for Mo-99 and **>3.5M** Lu-177 **doses**



One reactor. Two jobs. Multiple isotopes.

Eden's reactor was invented at Sandia National Labs and licensed exclusively to Eden. Its all-target design produces medical isotopes in two ways simultaneously — making it dramatically more efficient than any competitor.



JOB 1: U-235 FISSION

Fuel splits to produce **Mo-99**

JOB 2: ACTIVATION

Neutrons make **Lu-177**, **Cu-64**, & other activation isotopes

- **Small footprint**
  1.8 MW — small enough that the NRC reviews it as a research reactor (not a power plant).
- **Few moving parts**
  6 moving parts. Operates like a university research reactor; >98.5% uptime.
- **Passive safety**
  Cools itself by natural circulation. No emergency power or backup pumps required.
- **Mature technology**
  30+ years of Sandia R&D; TRL 7-8; exclusive Eden license from DOE.

Two production paths in a single, smaller, simpler reactor — the source of Eden's structural cost advantage.

Source: Eden Radioisotopes; Sandia National Laboratories

New Mexico Roots. National Infrastructure.

Eden's reactor was invented at Sandia National Laboratories and licensed exclusively to Eden — a New Mexico-born technology now going to work for the world.

Sandia Lab Technology

Eden's reactor was invented and patented by founders at Sandia National Labs — a 30-year R&D investment now commercialized. Commercial royalties from production flow back to Sandia, supporting future federal research programs.

National Security Asset

The U.S. currently depends on aging foreign reactors for critical isotope supply. Eden eliminates that vulnerability — and does so from New Mexico, the only state with a complete nuclear fuel system: uranium resources, enrichment (Urenco), national labs, and waste isolation (WIPP) all within its borders.

Federal Policy Alignment

Supports the 2012 American Medical Isotope Act and domestic nuclear infrastructure development. At the state level, New Mexico passed Senate Memorial 27 (RECA outreach, unanimous bipartisan support) and introduced SB 78 — the first nuclear energy legislation in NM history — signaling growing state alignment with Eden's mission.

Eden is proud to be a New Mexico company.
Building on the state's legacy of nuclear science leadership to create lasting infrastructure, lasting jobs, and lasting impact.

Putting New Mexico on the Map for Advanced Manufacturing

A $500M investment in Eunice, NM — home to Urenco's enrichment facility and the only location in the U.S. where a medical isotope reactor can source enriched fuel domestically, on-site.

$500M

Capital investment in New Mexico by 2030

125

Direct permanent jobs statewide (85 in Lea County)

$18-22M

Annual payroll statewide

$850M-$1B

Statewide economic activity from construction (2027-2029)

~$2.6B

Annual isotope revenue at full maturity

Workforce includes:
Nuclear engineers, reactor operators, radiation safety professionals, regulatory specialists, and technical staff

Eden joins a $9B+ annual nuclear economy in New Mexico — 35K+ jobs spanning national labs, WIPP, Urenco, and private industry.
Sending domestically-produced medical isotopes to patients around the world, all from Lea County.

NRC Licensing Pathway

Eden's Construction Permit Application has been docketed and is under NRC review.



Research reactor pathway

At 1.8 MW, the reactor is small enough that the NRC reviews it as a research reactor, not a power plant.

Review on schedule


The NRC schedule indicates a November 2027 review timeline for the construction permit, with commercial production planned for 2030.

Experienced licensing team

Led by Licensing Director Jim Saldarini (50 years of US NRC and DOE experience), with NRC advisors Alexander Adams Jr. and Anthony Mendiola.

Source: NRC Press Release No. 26-065 (June 16, 2026); Eden Radioisotopes

Path to revenue



2026

NRC construction permit application in review.

2026

June 16, 2026

Eden's CPA has been docketed by the NRC.

2026–2027

NRC licensing; Construction permit secured → Series B/C preparation.

Offtake agreements contracted.

2027–2029

Facility construction, equipment fabrication, QA and staffing.

2029–2030

Commissioning and regulatory verification.

2030

Initial isotope production (**Mo-99**, **Lu-177**, **Cu-64**) and contracted revenue (H2).

2031

Full-scale operations → expansion to new isotopes and export markets.

A team built for this moment

Proven at Every Stage of the Medical Isotopes Value Chain

CF

Carrie Freeman

Chief Executive Officer

3x CEO. Scaled technology with Intel, NASA, Worldbank. Mobilized $1.3B+ in capital and led operations across 160+ countries

CW

Chris Wagner

CCO & Co-Founder

40 years in nuclear medicine. Senior executive at Nordion and Curium — the world's largest medical isotope manufacturers.

EP

Ed Parma, Ph.D.

CSO & Co-Founder

30-year Sandia National Labs career. Inventor of Eden's reactor concept; 100+ publications in nuclear science.

SB

Scott Blumenfeld

Interim CFO

25+ years as a growth-stage CFO scaling technology companies. Trusted partner to founders and investors on financial infrastructure and operating discipline for Series B/C growth.

DA

Dillon Allen

COO

25 years of defense + utility nuclear experience. Led advanced nuclear dev at Entergy after Navy oversight of Virginia-class submarines and Ford-class carriers.

JS

Jim Saldarini

Licensing Director

50 years US NRC, DOE experience. Chief Nuclear and Environmental Engineer with Bechtel.

TS

Travis Steele

Executive Chairman

CEO of Abo Ventures, responsible for sourcing and negotiating private investments. Former partner at Butler Snow LLP with extensive corporate governance experience.

Advisors: Jigar Shah (DOE) · Nella Domenici (Financial) Alexander Adams Jr. (NRC) · Anthony Mendiola (NRC) · Jay Simon (Pharma)

Contact Information



eden | Precision Science. Human Impact.

info@edenrad.com

Carrie Freeman
Chief Executive Officer

cfreeman@edenrad.com
+1(505) 301-4574